For years, the FDA’s approach to compounded peptides has looked less like careful regulation and more like a campaign to eliminate patient access to products that compete with Big Pharma. There may at last be reason for cautious optimism. Action Alert!
Listen to the audio version of this story:
THE TOPLINE
- The FDA’s newly remade Pharmacy Compounding Advisory Committee will meet July 23-24, 2026, to consider whether key peptides—including BPC-157, KPV, TB-500, MOTs-C, Epitalon, and others—should be allowed for use by traditional compounding pharmacies.
- Unlike past panels that rejected access to peptides such as thymosin alpha-1, the new PCAC includes physicians and pharmacists with real-world experience in personalized, regenerative, and integrative medicine—raising cautious hope for a more balanced approach.
- FDA restrictions are pushing patients toward risky “research use only” gray-market products, while properly regulated compounding offers a safer path through physician oversight, pharmacy accountability, and enforceable quality standards.
For too long, patients seeking personalized peptide therapies have been forced into a cruel choice: go without treatments their doctors believe may help, or turn to the unsafe gray market created by FDA restrictions. Now, a newly remade FDA advisory panel could offer a rare opening to restore common sense, protect patients, and keep safe, natural peptides available through lawful, physician-supervised compounding.
The FDA’s Pharmacy Compounding Advisory Committee, or PCAC, has been remade with members who appear to understand what patients, physicians, and compounding pharmacists already know: access to properly compounded medicines can be a lifeline, especially when conventional medicine offers limited options. This is almost certainly due to RFK Jr.’s influence, and we commend him for taking this action to protect consumer choice.
That matters because PCAC is preparing to review another slate of peptides for potential inclusion on the FDA’s 503A Bulk Drug Substances List. The committee will meet July 23-24, 2026, to consider BPC-157, KPV, TB-500, MOTs-C, emideltide, Semax, and Epitalon.
PCAC’s Importance
PCAC does not make the final law. It advises the FDA.
For many peptides, however, the committee’s recommendation is a critical step. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a traditional compounding pharmacy may compound from a bulk drug substance only if the substance has a United States Pharmacopeia or National Formulary monograph, is a component of an FDA-approved drug, or appears on the 503A Bulks List.
If PCAC recommends adding a substance, the FDA must still go through notice-and-comment rulemaking before formally adding it. In other words, even a favorable PCAC vote is not an immediate green light. But a negative vote can help the FDA justify continued restriction.
That is why the composition of this committee matters so much.
A Needed Departure from the Old PCAC
Past PCAC panels have been dominated by academic and institutional voices that often appeared to accept the FDA’s framing rather than challenge it. The result has been predictable: peptide after peptide, and natural substance after natural substance, have been rejected.
At its December 4, 2024 meeting, PCAC voted against adding CJC-1295, AOD-9604, and thymosin alpha-1 to the 503A Bulks List. Thymosin alpha-1, or Ta1, was rejected by a vote of 17 to 4.
The remade roster looks different. FDA’s current PCAC roster includes physicians and pharmacists with expertise in cellular medicine, regenerative therapies, internal medicine, family medicine, pharmacy, and personalized medicine. Members include Asare B. Christian, MD, founder and medical director of Aether Medicine; Melissa Loseke, DO, owner and physician at Re-New Institute; Joshua Starbuck, MD, owner and physician at Makena Health; Kris Wusterhausen, DO, founder and medical director of The Resurge Clinic; and pharmacists Timothy Fensky and Tennessee State Senator Robert Harshbarger III.
Critics have attacked these appointments because some members work in clinics or businesses connected to peptides, hormone therapy, or regenerative medicine. The Associated Press reported that the new panel includes doctors and pharmacists with ties to the peptide and wellness space and contrasted it with prior panels made up mostly of academics and researchers.
But that criticism misses the point. Patients do not need another committee that treats real-world clinical experience as a liability. They need a committee willing to ask whether FDA policy is pushing patients toward greater danger or denying them access to safe and effective products.
The Thymosin Alpha-1 Warning
Thymosin alpha-1 (Ta1) shows what goes wrong when FDA treats natural peptides as regulatory threats.
Ta1 is a peptide naturally occurring in the thymus and has long been studied for immune-modulating properties. A 2020 review describes thymosin alpha-1 as naturally occurring in the thymus and notes its longstanding recognition for modifying, enhancing, and restoring immune function. The literature also describes Ta1 and thymalfasin as having well-studied safety profiles and being generally well tolerated, with mostly minor side effects.
Yet PCAC still rejected it.
The FDA has cited concerns including immunogenicity, possible impurities, and inadequate safety information for certain compounded uses.
As we’ve argued previously, lack of data does not imply risk. If impurities are the concern, FDA should issue clear quality-control guidance for compounding pharmacies and bulk ingredient suppliers. If route of administration is the issue, FDA should address route-specific safeguards.
For natural peptides with meaningful safety histories, the answer should be better standards, not prohibition.
Restriction Fuels the Gray Market
The FDA’s peptide crackdown has had a predictable consequence: patients have not stopped seeking peptides. Many have simply been pushed out of the medical system.
Products labeled “for research use only” are widely available online. These products—often imported from shady overseas suppliers—may have uncertain purity, questionable sterility, inaccurate labeling, or no meaningful medical oversight.
Properly regulated compounding offers a better path: physician oversight, patient-specific prescriptions, pharmacy accountability, certificates of analysis, and enforceable standards.
The FDA’s own 503A framework recognizes that bulk drug substances used in compounding must meet specific conditions, including valid certificates of analysis and manufacturing by registered establishments.
If FDA’s goal is patient safety, it should prefer licensed pharmacies over anonymous online sellers.
Epitalon Is Next
Epitalon deserves especially close attention at the July 24 meeting.
Epitalon is a tetrapeptide, Ala-Glu-Asp-Gly, also known as AEDG. It was synthesized based on the amino acid composition of Epithalamin, a bovine pineal gland extract, before being identified in pineal gland polypeptide complex solution. Like Ta1, Epitalon sits closer to the natural-peptide end of the spectrum than many new-to-nature compounds.
There are gaps in the safety data. But lack of complete data is not the same as evidence of harm, especially when used under the care of a physician through licensed compounding pharmacies.
Access to Epitalon is critically important. It sits at the heart of the life’s work of the pioneer of bioregulatory peptides, the late Prof. Vladimir Khavinson — a field he developed over more than four decades and described as “the future of medicine.” Khavinson regarded the pineal peptide system as a central regulator of biological resilience and ageing, and in his clinical framework Epitalon is often used as a foundational bioregulator alongside organ-specific peptide preparations. Removing physician-supervised access to Epitalon would therefore cut off one of the most important examples of a natural-sequence peptide approach that is biologically targeted, individualized, and fundamentally different from conventional drug intervention.
Stay Vigilant
ANH is preparing to defend access to key peptides through a petition focused on substances that are, above all, safe and natural. The peptide category is broad. Some substances are naturally occurring. Some are natural analogues. Others are essentially new-to-nature compounds that may warrant more caution.
Our priority is to protect access where the safety case is strongest and where patients and integrative physicians have the most to lose from FDA overreach.
The remade PCAC is not a guarantee. FDA career staff may still push the same restrictive assumptions. The agency may still hide behind speculative risks rather than engage with quality-control solutions. And even a favorable PCAC recommendation does not mean the FDA will take the committee’s advice.
But this is an opening.
Patients deserve access to personalized medicine. Physicians deserve tools beyond one-size-fits-all drugs. Compounding pharmacies deserve a regulatory system that rewards quality rather than punishes innovation. And FDA should not be allowed to drive patients into the gray market while claiming to protect them.
Action Alert!
